Description: Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Wilmington, DE.
Home Page: www.ayalapharma.com
AYLA Technical Analysis
4 Oppenheimer Street
Rehovot,
7670104
Israel
Phone:
857 444 0553
Officers
| Name | Title |
|---|---|
| Dr. Roni Mamluk M.D., Ph.D. | Pres, CEO & Director |
| Mr. Yossi Maimon CPA, CPA, M.B.A., MBA | CFO, Sec. & Treasurer |
| Dr. Gary B. Gordon M.D., Ph.D. | Chief Medical Officer |
| Dr. Shmuel Tuvia Ph.D. | Chief Scientific Officer |
| Ms. Irit Klipper Avni M.A. | VP of HR |
| Ms. Dana Gelbaum M.B.A., M.Sc. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0232 |
| Price-to-Sales TTM: | 4.7036 |
| IPO Date: | 2020-05-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 35 |